Pharmas to Feel Lure of Deals in China

Pharmas to feel lure of deals BEIJING - China's drug market is primed for "explosive growth," making companies there attractive targets for drugmakers that will soon lose patents on their most popular treatments, according to KPMG LLP. Products worth more than $30 billion will lose patent cover this year, leading more drugmakers to look into buying or joining with companies in China, the world's third-biggest drug market, according to a KPMG report released on Wednesday.